Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
39.72 EUR | -0.38% | +2.63% | +1.17% |
06-25 | Orion Obtains License to Market Navamedic's Parkinson's Disease Drug in Europe | MT |
06-24 | Navamedic ASA and Orion Corporation Sign License & Supply Agreement for Flexilev in Europe | CI |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- The company's Refinitiv ESG score, based on a ranking of the company relative to its industry, comes out particularly well.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- The company is in a robust financial situation considering its net cash and margin position.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- Analyst opinion has improved significantly over the past four months.
Weaknesses
- The firm trades with high earnings multiples: 23.08 times its 2024 earnings per share.
- The company's enterprise value to sales, at 4.07 times its current sales, is high.
- The company appears highly valued given the size of its balance sheet.
- The company is highly valued given the cash flows generated by its activity.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+1.17% | 5.99B | A- | ||
+55.18% | 815B | C+ | ||
+45.48% | 654B | B | ||
-6.68% | 354B | C+ | ||
+22.19% | 337B | B- | ||
+10.58% | 302B | C+ | ||
+17.87% | 247B | B+ | ||
+2.17% | 229B | A+ | ||
+12.93% | 219B | B- | ||
+9.93% | 171B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- ORNBV Stock
- Ratings Orion Oyj